ホーム › 尿路上皮（移行上皮）癌 › ニューヨーク › New York City

New York City、NYにおける尿路上皮（移行上皮）癌の臨床試験

New York Cityとその周辺地域（約30マイル以内）の拠点で、尿路上皮（移行上皮）癌に関する22件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。

公式研究テキスト（英語）

ここで研究参加者を募集していますか？このページの上部に表示できます — 30日間 $99 →

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

被験者募集中第1相

Exelixis Clinical Site #60, New York
Exelixis Clinical Site #6, New York

18歳以上 · 全性別 · 2026/10/01更新 · NCT05176483

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

被験者募集中第2相

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Memorial Sloan Kettering Cancer Center, New York
NYP/Weill Cornell Medical Center, New York

18歳以上 · 全性別 · 2026/09/30更新 · NCT03866382

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

被験者募集中観察研究

NYU Grossman School of Medicine, New York

18歳以上 · 全性別 · 2026/09/29更新 · NCT05874921

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

被験者募集中第1/2相

Memorial Sloan Kettering Cancer Center ( Site 1031), New York

18歳以上 · 全性別 · 2026/09/28更新 · NCT05562830

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

被験者募集中第1/2相

Icahn School of Medicine at Mount Sinai, New York

18歳以上 · 全性別 · 2026/09/28更新 · NCT07421700

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

被験者募集中第1相

Columbia University Irving Medical Center, New York

18歳以上 · 全性別 · 2026/09/28更新 · NCT07277413

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

被験者募集中第3相

Columbia University Irving Medical Center, New York
Memorial Sloan Kettering Cancer Center, New York
Weill Cornell Medical College, New York

18歳以上 · 全性別 · 2026/09/22更新 · NCT07218380

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

被験者募集中第1相

Mount Sinai Hospital, New York
NYP/Weill Cornell Medical Center, New York

18歳以上 · 全性別 · 2026/09/21更新 · NCT06439836

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

被験者募集中第2相

Memorial Sloan Kettering Cancer Center, New York

18歳以上 · 全性別 · 2026/09/17更新 · NCT05239624

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

被験者募集中第1相

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

18歳以上 · 全性別 · 2026/09/16更新 · NCT07532902

GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

被験者募集中第1/2相

Tisch Cancer Institute (TCI), Icahn School of Medicine, New York
Columbia University, New York

18歳以上 · 全性別 · 2026/09/14更新 · NCT04977453

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

被験者募集中第1相

Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York

18歳以上 · 全性別 · 2026/09/10更新 · NCT06293898

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

被験者募集中第1相

New York Cancer & Blood Specialists, New York

18歳以上 · 全性別 · 2026/08/27更新 · NCT06582017

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

被験者募集中第1/2相

NYU Langone Health, New York
Icahn School of Medicine At Mount Sinai Prime, New York

18歳以上 · 全性別 · 2026/08/05更新 · NCT06330064

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

被験者募集中第2相

Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
Icahn School of Medicine at Mount Sinai, New York
Evelyn H. Lauder Breast and Imaging Centre (BAIC), New York
他2件

18歳以上 · 全性別 · 2026/07/22更新 · NCT04879329